文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

磁性纳米簇武装响应性 PD-1 抗体协同增强用于实体瘤的过继性 T 细胞疗法。

Magnetic Nanoclusters Armed with Responsive PD-1 Antibody Synergistically Improved Adoptive T-Cell Therapy for Solid Tumors.

机构信息

School of Life Science , Beijing Institute of Technology , No. 5 South Street , Zhong Guan Cun, Beijing 100081 , China.

State Key Laboratory of Biochemical Engineering, Institute of Process Engineering , Chinese Academy of Sciences , 1 North Second Street , Zhong Guan Cun, Beijing 100190 , China.

出版信息

ACS Nano. 2019 Feb 26;13(2):1469-1478. doi: 10.1021/acsnano.8b07141. Epub 2019 Feb 18.


DOI:10.1021/acsnano.8b07141
PMID:30763076
Abstract

Although adoptive T-cell therapy has been successful in hematological malignancy treatment, its application in solid tumors remains a great challenge. Here, using a pH-sensitive benzoic-imine bond and inverse electron-demand Diels-Alder cycloaddition, we prepared magnetic nanoclusters (NCs) armed with responsive PD-1 antibody (aP), which could then bind onto effector T cells due to their PD-1 expression. After adoptive transfer, the magnetization and superparamagnetism of NCs enabled us to magnetically recruit effector T cells and aP simultaneously to tumor sites with MRI guidance. Owing to the acidic intratumoral microenvironment, the benzoic-imine bond then hydrolyzed, leading to the release of aP. The therapeutic effects of adoptive T cells and free aP could thus be spatiotemporally coupled. As a result, we achieved inhibition of tumor growth with few side effects, demonstrating the great promise of such a chemical approach for safe and high-performance adoptive T-cell therapy against solid tumors.

摘要

虽然过继性 T 细胞疗法在血液恶性肿瘤的治疗中已取得成功,但它在实体瘤中的应用仍然是一个巨大的挑战。在这里,我们使用 pH 敏感的苯甲酸亚胺键和反向电子需求 Diels-Alder 环加成反应,制备了带有响应性 PD-1 抗体 (aP) 的磁性纳米团簇 (NCs),由于其 PD-1 的表达,NCs 可以结合到效应 T 细胞上。在过继转移后,NCs 的磁化和超顺磁性使我们能够在 MRI 引导下将效应 T 细胞和 aP 同时磁募集到肿瘤部位。由于肿瘤内酸性微环境,苯甲酸亚胺键随后发生水解,导致 aP 的释放。因此,过继 T 细胞和游离 aP 的治疗效果可以时空偶联。结果,我们实现了肿瘤生长的抑制,副作用很少,这表明这种化学方法在安全高效的针对实体瘤的过继性 T 细胞治疗方面具有巨大的应用前景。

相似文献

[1]
Magnetic Nanoclusters Armed with Responsive PD-1 Antibody Synergistically Improved Adoptive T-Cell Therapy for Solid Tumors.

ACS Nano. 2019-2-18

[2]
Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.

Cancer Res. 2017-5-22

[3]
Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy.

Cancer Res. 2016-3-15

[4]
Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.

Clin Cancer Res. 2018-10-16

[5]
Blockade of PD-1/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment.

PLoS One. 2015-3-5

[6]
Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.

Clin Cancer Res. 2016-1-15

[7]
Expansion of Tumor-Infiltrating CD8 T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy.

Cancer Res. 2017-5-18

[8]
T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma.

J Immunother. 2016

[9]
Adoptive cell therapy using PD-1 myeloma-reactive T cells eliminates established myeloma in mice.

J Immunother Cancer. 2017-6-20

[10]
Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.

J Immunol. 2016-9-15

引用本文的文献

[1]
Smart CAR-T Nanosymbionts: archetypes and proto-models.

Front Immunol. 2025-8-12

[2]
A bibliometric analysis of challenges and advancements in the integrated application of nanoparticles and chimeric antigen receptor T cell therapy.

Hum Vaccin Immunother. 2025-12

[3]
Immune response recalibration using immune therapy and biomimetic nano-therapy against high-grade gliomas and brain metastases.

Asian J Pharm Sci. 2025-4

[4]
Advances in bioengineered CAR T/NK cell therapy for glioblastoma: Overcoming immunosuppression and nanotechnology-based strategies for enhanced CAR T/NK cell therapy.

Bioeng Transl Med. 2024-8-31

[5]
SynBioNanoDesign: pioneering targeted drug delivery with engineered nanomaterials.

J Nanobiotechnology. 2025-3-6

[6]
Enhancing immunotherapy with tumour-responsive nanomaterials.

Nat Rev Clin Oncol. 2025-4

[7]
Loading of CAR-T cells with magnetic nanoparticles for controlled targeting suppresses inflammatory cytokine release and switches tumor cell death mechanism.

MedComm (2020). 2025-1-5

[8]
CAR T Cell Nanosymbionts: Revealing the Boundless Potential of a New Dyad.

Int J Mol Sci. 2024-12-7

[9]
Ultrasound-Activated Precise Sono-Immunotherapy for Breast Cancer with Reduced Pulmonary Fibrosis.

Adv Sci (Weinh). 2025-2

[10]
Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy.

J Transl Med. 2024-8-9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索